Bernard B. Beaulieu

591 total citations
21 papers, 437 citations indexed

About

Bernard B. Beaulieu is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Bernard B. Beaulieu has authored 21 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Surgery and 6 papers in Oncology. Recurrent topics in Bernard B. Beaulieu's work include Clostridium difficile and Clostridium perfringens research (4 papers), Testicular diseases and treatments (3 papers) and Veterinary Oncology Research (3 papers). Bernard B. Beaulieu is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (4 papers), Testicular diseases and treatments (3 papers) and Veterinary Oncology Research (3 papers). Bernard B. Beaulieu collaborates with scholars based in United States, United Kingdom and Serbia. Bernard B. Beaulieu's co-authors include Peter Goldman, Ronald L. Koch, Ewan J. T. Chrystal, William J. Ehlhardt, Martha A. McLafferty, Lionel D. Lewis, Alan Eastman, Gillian Sudlow, C. Harker Rhodes and Raymond P. Perez and has published in prestigious journals such as Science, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Bernard B. Beaulieu

19 papers receiving 404 citations

Peers

Countries citing papers authored by Bernard B. Beaulieu

Since Specialization

Citations

This map shows the geographic impact of Bernard B. Beaulieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard B. Beaulieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard B. Beaulieu more than expected).

Fields of papers citing papers by Bernard B. Beaulieu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard B. Beaulieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard B. Beaulieu. The network helps show where Bernard B. Beaulieu may publish in the future.

Co-authorship network of co-authors of Bernard B. Beaulieu

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard B. Beaulieu. A scholar is included among the top collaborators of Bernard B. Beaulieu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard B. Beaulieu. Bernard B. Beaulieu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Accrual of historically underrepresented patients with multiple myeloma using centralized screening in a multicenter study. 2025 ·Journal of Clinical Oncology ·Anosheh Afghahi, (unknown), Yichen Lu, (unknown), Laura Hester, Dina Gifkins, Bernard B. Beaulieu, C Cipolla, (unknown), Debra Mitchell, (unknown), (unknown), Hemang Patel, (unknown), C Salzman, Neal J. Meropol, (unknown)	0
2	Adequacy of oral intakes after cardiac surgery within an ERAS pathway: A prospective observational study 2024 ·Nutrition in Clinical Practice ·Bernard B. Beaulieu, Yoan Lamarche, (unknown), (unknown)	1
3	A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue 2013 ·Breast Cancer Research and Treatment ·(unknown), Burton Eisenberg, Lionel D. Lewis, Heather M. Froehlich, Wendy A. Wells, Alan Eastman, Nancy B. Kuemmerle, (unknown), Richard J. Barth, Gary N. Schwartz, Zhongze Li, Tor D. Tosteson, Bernard B. Beaulieu, William B. Kinlaw	32
4	Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer 2012 ·Veterinary and Comparative Oncology ·(unknown), Cheryl E. Balkman, (unknown), Michael A. Kiselow, Andrea B. Flory, Bernard B. Beaulieu, Lionel D. Lewis, Michael F. McEntee	2
5	Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs 2008 ·American Journal of Veterinary Research ·Andrea B. Flory, Kenneth M. Rassnick, Cheryl E. Balkman, Michael A. Kiselow, (unknown), Bernard B. Beaulieu, Lionel D. Lewis	12
6	Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs 2008 ·Journal of the American Veterinary Medical Association ·Andrea B. Flory, Kenneth M. Rassnick, Cheryl E. Balkman, Michael A. Kiselow, (unknown), Bernard B. Beaulieu, Lionel D. Lewis	1
7	Phase I and Pharmacokinetic Evaluation of the Combination of Orally Administered Docetaxel and Cyclosporin A in Tumor-Bearing Cats 2006 ·Journal of Veterinary Internal Medicine ·Margaret C. McEntee, Kenneth M. Rassnick, Dennis B. Bailey, Cheryl E. Balkman, (unknown), Bernard B. Beaulieu, (unknown), Lionel D. Lewis, Rodney L. Page	5
8	Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs 2006 ·American Journal of Veterinary Research ·Margaret C. McEntee, Kenneth M. Rassnick, Lionel D. Lewis, (unknown), Bernard B. Beaulieu, Cheryl E. Balkman, Rodney L. Page	10
9	Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas 2006 ·American Journal of Veterinary Research ·Kenneth M. Rassnick, Antony S. Moore, Nicole C. Northrup, Orna Kristal, Bernard B. Beaulieu, Lionel D. Lewis, Rodney L. Page	12
10	Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850) 2006 ·Clinical Cancer Research ·Raymond P. Perez, Lionel D. Lewis, Andrew P. Beelen, Anthony J. Olszanski, Nicholas Johnston, C. Harker Rhodes, Bernard B. Beaulieu, Marc S. Ernstoff, Alan Eastman	52
11	Histoire administrative du ministère de la culture, 1959-2002 : les services de l'administration centrale 2002 ·Documentation française eBooks ·Bernard B. Beaulieu, (unknown)	1
12	Nitrosoimidazoles: highly bactericidal analogs of 5-nitroimidazole drugs 1988 ·Journal of Medicinal Chemistry ·William J. Ehlhardt, Bernard B. Beaulieu, Peter Goldman	21
13	Mammalian cell toxicity and bacterial mutagenicity of nitrosoimidazoles 1988 ·Biochemical Pharmacology ·William J. Ehlhardt, Bernard B. Beaulieu, Peter Goldman	12
14	Formation of an amino reduction product of metronidazole in bacterial cultures: Lack of bactericidal activity 1987 ·Biochemical Pharmacology ·William J. Ehlhardt, Bernard B. Beaulieu, Peter Goldman	16
15	Chemical and biological properties of acetyl derivatives of the hydroxylamino reduction products of metronidazole and dimetridazole 1987 ·Biochemical Pharmacology ·William J. Ehlhardt, Bernard B. Beaulieu, Peter Goldman	4
16	Comparing the reduction of nitroimidazoles in bacteria and mammalian tissues and relating it to biological activity 1986 ·Biochemical Pharmacology ·Peter Goldman, Ronald L. Koch, (unknown), Ewan J. T. Chrystal, Bernard B. Beaulieu, Martha A. McLafferty, Gillian Sudlow	54
17	Interaction of metronidazole with DNA repair mutants of Escherichia coli 1984 ·Antimicrobial Agents and Chemotherapy ·(unknown), Bernard B. Beaulieu, Martha A. McLafferty, Peter Goldman	18
18	Metronidazole Metabolism in Cultures of Entamoeba histolytica and Trichomonas vaginalis 1981 ·Antimicrobial Agents and Chemotherapy ·Bernard B. Beaulieu, Martha A. McLafferty, Ronald L. Koch, Peter Goldman	17
19	A Metronidazole Metabolite in Human Urine and Its Risk 1981 ·Science ·(unknown), Bernard B. Beaulieu, Ewan J. T. Chrystal, Peter Goldman	39
20	Role of the intestinal flora in the metabolism of misonidazole 1980 ·Biochemical Pharmacology ·Ronald L. Koch, Bernard B. Beaulieu, Peter Goldman	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact